Clinical Scorecard: Survival With Lu-177 PSMA Therapy in Prostate Cancer: Outcomes by Treatment Line and Taxane Sequence
At a Glance
Category
Detail
Condition
Metastatic androgen pathway modulator–resistant prostate cancer
Key Mechanisms
Lu-177 PSMA-617 is a PSMA-directed radioligand therapy that carries Lu-177 to PSMA-expressing tumor cells.
Target Population
Patients with metastatic androgen pathway modulator–resistant prostate cancer who received an androgen receptor pathway inhibitor before Lu-177 PSMA.
Care Setting
US community and academic oncology practices represented in an EHR-derived retrospective cohort.
Key Highlights
The retrospective cohort included 850 patients; median age was 74 years.
Overall median clinical time to next treatment was 8.5 months (95% CI, 8.0-9.2), and median clinical overall survival was 13.0 months (95% CI, 12.0-14.0).
Lu-177 PSMA was administered in the third or fourth treatment line for 434 patients (51.1%).
Taxane exposure preceded Lu-177 PSMA in 466 patients (54.8%); 349 (41.1%) had no taxane exposure, and 35 (4.1%) received taxane afterward.
The authors reported that outcomes were generally similar across treatment lines and taxane-sequencing groups; analyses were descriptive and did not include hypothesis testing.
Guideline-Based Recommendations
Diagnosis
Management
The article describes Lu-177 PSMA use in patients with mAPMR prostate cancer previously treated with an ARPI, including taxane-naive patients whose disease progressed during ARPI treatment.
The study assessed outcomes by treatment line and taxane-exposure timing; analyses were descriptive and did not include hypothesis testing.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
850 patients with metastatic androgen pathway modulator–resistant prostate cancer who had received an androgen receptor pathway inhibitor before Lu-177 PSMA; median age 74 years (IQR, 68-80).
Overall median clinical time to next treatment was 8.5 months and median clinical overall survival was 13.0 months. By taxane timing, median time to next treatment and overall survival were 8.0 and 12.0 months after prior taxane, 10.0 and 14.0 months with no taxane exposure, and 6.0 and 16.0 months when taxane followed Lu-177 PSMA.
Clinical Best Practices
Interpret the reported survival estimates as descriptive observational outcomes, not comparative treatment effects; the analyses included no hypothesis testing.
Consider the study population and setting when applying results: data came from US community and academic practices, and most patients were treated in community settings.
